SCHEMBL1359908

SCHEMBL1359908

Cc1cn2c(=O)c(OCc3ccccc3)c(-c3ncc(Cc4ccc(F)cc4)s3)nc2s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
CYP1A2 P05177 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39
HSD17B10 Q99714 2/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
POLB P06746 3/20 0.38
CYP3A4 P08684 3/20 0.38
TSHR P16473 2/20 0.38
CYP2C9 P11712 2/20 0.38
USP2 O75604 1/20 0.38
TP53 P04637 6/20 0.36
MAPT P10636 2/20 0.36
HPGD P15428 4/20 0.36
LMNA P02545 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
KDM4E B2RXH2 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1359897 0.91 MAPT (0.42) ALDH1A1CYP1A2MEN1KMT2ACASP1
SCHEMBL1360524 0.88 TP53 (0.36) ALDH1A1CYP1A2MEN1KMT2ASMN1; SMN2
SCHEMBL12140788 0.88 POLB (0.37) ALDH1A1MEN1KMT2ASMN1; SMN2POLB
SCHEMBL1361685 0.87 NR1I3 (0.39) SMN1; SMN2POLBTP53MAPTLMNA
SCHEMBL1150727 0.82 CYP1A2 (0.41) ALDH1A1CYP1A2MEN1KMT2ACASP1
SCHEMBL1360637 0.82 SMN1; SMN2 (0.41) ALDH1A1MEN1KMT2ASMN1; SMN2POLB
SCHEMBL823415 0.77 SLC2A1 (0.45) ALDH1A1CYP1A2MEN1KMT2ACASP1
SCHEMBL12140420 0.76 MAPT (0.35) SMN1; SMN2POLBTP53MAPTLMNA
SCHEMBL1151420 0.76 KDM1A (0.37) ALDH1A1CYP1A2MEN1KMT2ACASP1
SCHEMBL1221754 0.76 CYP3A4 (0.38) ALDH1A1CYP1A2MEN1KMT2ACASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426405-B2 Thiazopyrimidinones and uses thereof AVEXA LIMITED (AU) 2013-04-23 US disclosed
US-8426405-B2 Thiazopyrimidinones and uses thereof AVEXA LIMITED (AU) 2013-04-23 US disclosed
EP-2247601-B1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LTD (AU) 2013-04-10 EP disclosed
US-20110281861-A1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2011-11-17 US disclosed
US-20110281861-A1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281861-A1 THIAZOPYRIMIDINONES AND USES THEREOF TPMT, CYP2C19, CYP3A5 ALDH1A1 124/4885CYP1A2 70/4885MEN1 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.